At A Glance:

This sponsor had blockbuster expectations for its compound in the treatment of moderate-to-severe atopic dermatitis when it began its Phase III study.

Download PDF
Indication:

Atopic Dermatitis

Randomized patients delivered: 25%
Enrollment cost saved: $2.2 million
See the results
Case Study

AES Shortens Timelines by up to 20 Months for a Uterine Fibroid Program

VIEW CASE STUDY >
Case Study

AES Helped to Put a Sponsor at the Forefront of a Chronic Disease Market

VIEW CASE STUDY >
Case Study

AES saves up to 76 months of enrollment time for this pediatric depression program

VIEW CASE STUDY >
Case Study

Thanks to AES, a Sponsor Won its Race to Market with a New Class of OIC Drug

VIEW CASE STUDY >
Case Study

AES Shortens Enrollment by 7 Months for a Crucial Migraine Phase IIb Study

VIEW CASE STUDY >